DYRK1B and ovarian carcinoma: Thus the kinase Mirk/dyrk1B appears to be a new therapeutic target in ovarian cancer ascites, in particular when added together with the mTOR specific inhibitor RAD001 (everolimus), a drug already in clinical use (27), (28).